Feasibility study for the long-term management of refractory hyperkeratotic eczema with calcipotriol and betamethasone dipropionate (Daivobet ® ), viaminate and concomitant conventional therapies: a retrospective study

Mafuru, Magesa

Feasibility study for the long-term management of refractory hyperkeratotic eczema with calcipotriol and betamethasone dipropionate (Daivobet ® ), viaminate and concomitant conventional therapies: a retrospective study

dc.contributor.author	Mafuru, Magesa
dc.date.accessioned	2022-01-26T10:47:23Z
dc.date.available	2022-01-26T10:47:23Z
dc.date.issued	2020
dc.description.abstract	Background: The available treatments for refractory hyperkeratotic eczema are inadequate with frustrating results. We, therefore, incorporated Calcipotriol and Betamethasone Dipropionate (Daivobet®), and Viaminate into the mainstay treatment to improve the clinical symptoms. The study aimed to evaluate the efficacy of Daivobet® and Viaminate as a potential treatment alternative for refractory hyperkeratotic eczema. Patients and Methods: Between 2013 and 2015, 61 patients diagnosed with refractory hyperkeratotic eczema (RHE) who had shown inadequate response to conventional therapies were pooled from a single center. Besides, they were all treated with Daivobet®, Viaminate, and an occlusive dressing mixture containing 5% salicylic acid ointment and 25% zinc oxide paste following inadequate response to conventional therapies (corticosteroids plus 25% zinc oxide paste and 5% salicylic acid ointment). Investigators Global Assessment (IGA) and Patient-Oriented Eczema Measure (POEM) assessed baseline and outcome measures for the degree of hyperkeratinization (0-clear; 3-moderate; 4-severe). Results: Of the 61 patients, 49 (80.3%) patients presented with moderate RHE and 12 (19.7%) with severe RHE. After 24 weeks of treatment, the period for loss of keratinization was significantly lower in patients with moderate RHE (3.9±1.9 weeks) than those with severe RHE (10.8±1.0 weeks) with a P-value <0.01. Furthermore, they required a significantly shorter total treatment duration (10.6 ± 4.3 weeks) than those with severe RHE (20.3±3.6 weeks) with a P-value of <0.01. However, there were no significant differences in post hoc analysis at week 36 with P-values of 0.46 and 1.00 for IGA and POEM, respectively. Conclusion Our results showed that the incorporation of Viaminate and Daivobet® into mainstay treatment was effective and safe for the long-term management of RHE.	en_US
dc.identifier.citation	Nabatanzi, A., Mafuru, M., Male, M., Tian, C., Zhang, L., Wu, T., Wu, S. and Huang, C., 2020. Feasibility Study for the Long-Term Management of Refractory Hyperkeratotic Eczema with Calcipotriol and Betamethasone Dipropionate (Daivobet®), Viaminate and Concomitant Conventional Therapies: A Retrospective Study. Clinical, Cosmetic and Investigational Dermatology, 13, p.789.	en_US
dc.identifier.other	doi: 10.2147/CCID.S276148
dc.identifier.uri	http://hdl.handle.net/123456789/879
dc.language.iso	en	en_US
dc.publisher	Cosmetic and Investigational Dermatology.	en_US
dc.subject	Eczema	en_US
dc.subject	Hyperkeratosis	en_US
dc.subject	Refractory	en_US
dc.title	Feasibility study for the long-term management of refractory hyperkeratotic eczema with calcipotriol and betamethasone dipropionate (Daivobet ® ), viaminate and concomitant conventional therapies: a retrospective study	en_US
dc.type	Article	en_US